Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Clinical Implications of Nocebo Effects for Biosimilar Therapy
Luana Colloca, Remo Panaccione, T.K. Murphy
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 87

Showing 26-50 of 87 citing articles:

The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review
E. Hillhouse, Karine Mathurin, J. Bibeau, et al.
Advances in Therapy (2021) Vol. 39, Iss. 1, pp. 455-487
Open Access | Times Cited: 16
Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
Zvonimir Petrić, João Gonçalves, Paulo Paixão
Pharmaceutics (2022) Vol. 14, Iss. 9, pp. 1766-1766
Open Access | Times Cited: 12
Moving forward: Implementing health psychology research to improve patient acceptance of biosimilars
Chiara Gasteiger, Keith J. Petrie
Research in Social and Administrative Pharmacy (2022) Vol. 18, Iss. 10, pp. 3860-3863
Closed Access | Times Cited: 11
Efficacy, safety and immunogenicity of etanercept biosimilars versus reference biologics in patients with rheumatoid arthritis: A meta-analysis
Rui Hu, Tao Yuan, Hui Wang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 6
The Nocebo Effect: A Bias in Clinical Practice—An Ethical Approach
Iulia-Virginia Răducan-Florea, Florin Leașu, Eleonora Dinu, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 5, pp. e541-e549
Closed Access | Times Cited: 2
Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study
Stephanie L. Ho, Fang Niu, Suresh Pola, et al.
BioDrugs (2020) Vol. 34, Iss. 3, pp. 395-404
Open Access | Times Cited: 17
Knowledge, Attitudes and Practice of Healthcare Providers, Healthcare Regulatory Practitioners and Patients Toward Biosimilars in China: Insights From a Nationwide Survey
Yang Hu, Zaiwei Song, Dan Jiang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 10
Factors associated with the uptake of biosimilars for breast cancer treatment from the perspectives of physicians and patients-Evidence from China
Qiyou Wu, Zhiwei Lian, Xin Wang, et al.
Frontiers in Pharmacology (2023) Vol. 13
Open Access | Times Cited: 6
Exploring the emotional impact of axial Spondyloarthritis: a systematic review and thematic synthesis of qualitative studies and a review of social media
Nicky Wilson, Jia Liu, Qainat Adamjee, et al.
BMC Rheumatology (2023) Vol. 7, Iss. 1
Open Access | Times Cited: 6
Cost-efficiency and expanded access modeling of conversion to biosimilar trastuzumab-dkst with or without pertuzumab in metastatic breast cancer
Ali McBride, Karen MacDonald, Adolfo Fuentes‐Alburo, et al.
Journal of Medical Economics (2021) Vol. 24, Iss. 1, pp. 743-756
Open Access | Times Cited: 14
Does Similarity Breed Contempt? A Review of the Use of Biosimilars in Inflammatory Bowel Disease
Shubha Bhat, Jimmy K. Limdi, Raymond K. Cross, et al.
Digestive Diseases and Sciences (2021) Vol. 66, Iss. 8, pp. 2513-2532
Closed Access | Times Cited: 14
The global landscape on interchangeability of biosimilars
Anurag S. Rathore, James G. Stevenson, Hemlata Chhabra, et al.
Expert Opinion on Biological Therapy (2021) Vol. 22, Iss. 2, pp. 133-148
Closed Access | Times Cited: 13
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Kuan Peng, Joseph E. Blais, Nicole Pratt, et al.
BioDrugs (2023) Vol. 37, Iss. 3, pp. 409-420
Open Access | Times Cited: 5
The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease
Ulf Müller‐Ladner, Axel Dignaß, Karl Gaffney, et al.
BioDrugs (2023) Vol. 37, Iss. 6, pp. 873-889
Open Access | Times Cited: 5
Biosimilars are becoming indispensable in the management of multiple diseases although concerns still exist
Brian Godman
Bangladesh Journal of Medical Science (2020) Vol. 20, Iss. 1, pp. 5-10
Open Access | Times Cited: 13
Pharmacist biosimilar survey reveals knowledge gaps
James G. Stevenson, Dorothy McCabe, Melissa McGrath, et al.
Journal of the American Pharmacists Association (2022) Vol. 63, Iss. 2, pp. 529-537.e7
Closed Access | Times Cited: 8
TNF-alpha inhibitors biosimilar use in France: a nationwide population-based study using the French National Health Data System
H. Jourdain, Léa Hoisnard, É. Sbidian, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 8
Availability and accessibility of monoclonal antibodies in Bosnia and Herzegovina: Findings and implications
Biljana Tubić, Vanda Marković‐Peković, Saša Jungić, et al.
Medicine Access Point of Care (2021) Vol. 5
Open Access | Times Cited: 11
Nocebo Hyperalgesia in Patients With Fibromyalgia and Healthy Controls: An Experimental Investigation of Conditioning and Extinction Processes at Baseline and 1-Month Follow-up
Merve Karacaoglu, Kaya J. Peerdeman, Mattijs E. Numans, et al.
Journal of Pain (2023) Vol. 24, Iss. 9, pp. 1696-1711
Open Access | Times Cited: 4
Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database
Orhon Pauline, Marion Robert, Claire Bernardeau, et al.
BioDrugs (2023) Vol. 37, Iss. 5, pp. 699-707
Closed Access | Times Cited: 4
Factors that Influence Healthcare Professionals' Intentions towards Biosimilars
Mohammed Al Qahtani, Ahmed Al‐Jedai, Albert I. Wertheimer
INNOVATIONS in pharmacy (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52
Steven R. Feldman, Joanna Narbutt, Giampiero Girolomoni, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 1
Biosimilars are essential for sustainable healthcare systems; however, key challenges remain as seen with long-acting insulin analogues
Godman Brian, Tubic Biljana, Allocati Eleonora, et al.
Journal of Applied Pharmaceutical Science (2022)
Open Access | Times Cited: 7
Patient-Reported Outcomes in Rheumatoid Arthritis: A Key Consideration for Evaluating Biosimilar Uptake?
Gabriel Horta‐Baas
Patient Related Outcome Measures (2022) Vol. Volume 13, pp. 79-95
Open Access | Times Cited: 7
Continuous effectiveness and safety after a hospital‐wide switch to adalimumab biosimilar: An observational study in rheumatoid arthritis patients
Rianne Brouwer, Peter M. ten Klooster, Joost B. Masselink, et al.
Pharmacology Research & Perspectives (2022) Vol. 10, Iss. 6
Open Access | Times Cited: 7

Scroll to top